A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
Start Date
12/5/2024
Completion Date
7/17/2028
Summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Eligibility Criteria
Age Range: 12 years to 30 years
Interventions
V350A
V350B
Placebo
Conditions
Locations
California Clinical Trials Medical Group managed by PAREXEL ( Site 0011)
Glendale, California 91206
United States
QPS-MRA, LLC ( Site 0012)
South Miami, Florida 33143
United States
Alliance for Multispecialty Research, LLC ( Site 0008)
Kansas City, Missouri 64114
United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)
Springfield, Missouri 65802
United States
Velocity Clinical Research Lincoln ( Site 0004)
Lincoln, Nebraska 68510
United States
Velocity Clinical Research, Omaha ( Site 0005)
Omaha, Nebraska 68134
United States
Remington-Davis, Inc. ( Site 0017)
Columbus, Ohio 43215
United States
Lynn Health Science Institute ( Site 0010)
Oklahoma City, Oklahoma 73112
United States
Alliance for Multispecialty Research, LLC ( Site 0009)
Knoxville, Tennessee 37909
United States